SCHEMBL6000530

SCHEMBL6000530

CCCC(CCC)c1ccc(Cn2c(-c3csc(CN4CCN(c5cccc(C(=O)O)c5)CC4)n3)nc3ccccc32)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.42
KDM4E B2RXH2 2/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
AGTR1 P30556 3/20 0.39
AGTR2 P50052 3/20 0.39
HRH3 Q9Y5N1 5/20 0.38
NPSR1 Q6W5P4 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
BRD4 O60885 4/20 0.37
ALDH1A2 O94788 2/20 0.36
ALDH1A1 P00352 2/20 0.36
ALDH2 P05091 2/20 0.36
ALDH3A1 P30838 2/20 0.36
ALDH1A3 P47895 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6000162 0.85 CA12 (0.41)
SCHEMBL6000961 0.85 AGTR1 (0.43) PPARGAGTR1AGTR2HRH3GRM2
SCHEMBL6000662 0.84 AGTR1 (0.40) PPARGAGTR1AGTR2HRH3BRD4
SCHEMBL6001025 0.82 BRD4 (0.48) SMN1; SMN2BRD4
SCHEMBL5999093 0.81 PTPN2 (0.53) SMN1; SMN2KMT2AALDH1A1
SCHEMBL6000725 0.71 PTPN2 (0.55) KDM4EHRH3SMN1; SMN2MAPTMAPK1
SCHEMBL6000163 0.71 PTPN2 (0.55) KDM4EHRH3SMN1; SMN2MAPTMAPK1
SCHEMBL5999795 0.70 RXRA (0.43) AGTR1AGTR2SMN1; SMN2GAAMAPT
SCHEMBL5999945 0.70 CA12 (0.39) PPARGKDM4EOPRM1OPRD1SMN1; SMN2
SCHEMBL6000477 0.69 PTPN2 (0.53) HRH3SMN1; SMN2GAAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-06-08 US claimed
EP-1553091-A1 HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2005-07-13 EP claimed
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-06-08 US disclosed
EP-1553091-A1 HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof PTPN11, PTPN1, PTPN3 PPARG 435/4885KDM4E 1731/4885OPRM1 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.